Anzeige
Mehr »
Lynx Broker
Login
Montag, 14.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
SoPfizer takes aim at a flagship franchise at Sanofi and Regeneron - and scores a few direct hits1
SoStealth BioTherapeutics Does The Deal With Alexion, And Other Headlines: The Good, Bad And Ugly Of Biopharma6
SaBetter Buy: Gilead Sciences vs. Johnson & Johnson41
SaFlexion: Buying Before And After ZILRETTA's PDUFA1
SaIncyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo1.244Data presented at EADV demonstrate continued improvement in repigmentation of vitiligo lesions upon longer treatment duration with ruxolitinib cream Incyte (Nasdaq:INCY) today announces positive...
► Artikel lesen
SaAdverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC ...1
FrHEXO, ZEN and LXRX among after hours movers4
FrRetrophin, Inc.: Retrophin Announces Presentation of Abstracts at ASN Kidney Week 20191
FrApellis Pharmaceuticals, Inc.: Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week ...1
FrProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - Slideshow-
FrHere's Why Aerie Pharmaceuticals Rose as Much as 21.8% Today2
FrMid-Day Market Update: Crude Oil Up 1.5%; Aclaris Therapeutics Shares Jump5
FrHorizon Therapeutics' Phase 3 trial finds 'significant benefit' of teprotumumab1
FrClovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn8
FrCourt green-lights Clovis case after detailing evidence the board 'ignored red flags' on false safety and efficacy data5
FrNorthwest Bio still hanging on; Five Prime's latest round of layoffs claims 701
FrFibroGen, Inc: Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented ...3
FrLong term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor16
FrReata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 20192
FrSeattle Genetics Up More Than 20% in 3 Months: Here's Why1
Seite:  Weiter >>